Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Lymphoma lymphoma

Type Lymphoma Hodgkin Lymphoma Lymphoma Lymphoma Lymphoma... [Pg.148]

Lymphomas. Lymphomas are cancers derived from the B cells of the immune system. Reactivation or coinfection in the B lymphocytes with Epstein-Barr virus may be important in the development of lymphomas in AIDS patients. An unusual lymphoma that spreads to the brain also occurs. [Pg.211]

Steinberg, R. A. A kinase-negative mutant of s49 mouse lymphoma cells is defective in posttranslational maturation of catalytic subunitof cyclic amp-dependent protein kinase. Mol. Cell Biol. 11 (1991) 705-712. [Pg.196]

Lymphoid cells Lymphomas Lymphosarcoma Lyochrome Lyophilization... [Pg.581]

USP (Oncovin) vindesine sulfate [59917-39 ] C43H55N5O7 -H2S0 852.01 (50) chil-dren lymphocytic leukemia Hodgkin s disease non-Hodg-kin s lymphomas Wilm s tumor neuroblastoma rhabdomyosarcoma, investigational dmg (paresthesias, foot drop, double vision, etc) constipation ileus alopecia leu-kopenia (occasional) ... [Pg.441]

Despite dramatic advances in the treatment of several human malignancies including Hodgkin s lymphomas and leukemias, dmg resistance remains a pressing issue in cancer chemotherapy. Acquired or induced dmg resistance afflicts practically all classes of cancer agents. It usually is manifested clinically... [Pg.444]

Ricin [9009-86-3], a phytotoxin found in the seeds of the castor oil plant Acinus communis, conjugated to murine monoclonal antibody (Immunogen Corp.), has been approved by the U.S. Food and Dmg Administration (FDA) for the treatment of patients with B-ceU leukemia and lymphoma (59). [Pg.309]

L-asparaginase therapy with an extra-corporeal device in patients with malignant lymphoma has resulted in repeated remissions of metastases (242). This technique utilizes L-asparaginase covalentiy bound to the surface of a battery of plates contained in a portable chamber which has been inserted between an artery and vein. [Pg.312]

Poly(ethylene glycol) (PEG) molecules attached to adenosine deaminase (ADA) have been used in patients exhibiting symptoms of the severe combined immunodeficiency syndrome (SCID) caused by ADA deficiency. The modified enzyme has a plasma half-life of weeks as compared to the unmodified enzyme (minutes) (248). PEG-L-asparaginase has induced remissions in patients with non-Hodgkin s lymphoma (248). However, one disadvantage of PEG-enzyme treatment is its expense, ie, a year s treatment costs about 60,000 (248). [Pg.312]

In an animal study of rats exposed by inhalation to ethylene oxide at 10, 33, or 100 ppm for approximately two years (245), and in a separate chronic rat study in which rats were exposed to 50 or 100 ppm of ethylene oxide (240), increased incidences of mononuclear cell leukemia, peritoneal mesothelioma, and various brain tumors have been reported. In an NTP (246) two-year inhalation study of mice at 50 and 100 ppm, alveolar/bronchiolar carcinomas and adenomas, papillary cystadenomas of the harderian gland, and malignant lymphomas, uterine adenocarcinomas, and mammary gland tumors were increased in one or both exposure groups. [Pg.464]

When the data as a whole are reviewed for studies on humans exposed to ethylene oxide, no conclusion can be made that there is an increase in mortahty associated with those exposed to ethylene oxide. Two Swedish studies (247,248) indicated an increase in leukemia for workers exposed to multiple chemicals including ethylene oxide however, in a recent larger Swedish study (249) of workers exposed to only ethylene oxide, there was no association of any type of cancer increase for these workers. In a recent study sponsored by NIOSH, there was no significant increase in mortahty observed for cancer when all types are combined or for certain individual types of cancer, even for those people who worked the longest and were observed the longest. However, a statistically significant increase in mortahty from certain types of lymphoma was observed for male workers. This is contrary to the results observed for female workers. In addition, four other cohort studies of ethylene oxide-exposed workers have been pubhshed (250—253), but no unequivocal increase in the risk of cancer was observed. [Pg.464]

Histones (from S4A mouse lymphoma). Purification used a macroprocess column, heptafluorobutyric acid as solubilising and ion-pairing agent and an acetonitrile gradient. [McCroskey et al. Anal Biochem 163 427 1987.]... [Pg.541]

Vinyl chloride Liver - angiosarcoma Brain Lung - carcinoma Lymphatic system - lymphoma... [Pg.80]

AIDS (acquired immunodeficiency syndrome) is the final stage of disease caused by infection with HIV. In this stage, the vims infection has severely affected the immune system, causing a depletion of CD4+ T-helper cells. AIDS is characterized by the manifestation of typical diseases caused by opportunistic infections (Pneumocystis carinii pneumonia, CMV retinitis, candidiasis of the esophagus, cerebral toxoplasmosis), neurological manifestations, cachexia, or certain tumors (Kaposi sarcoma of the skin, B-cell lymphoma). [Pg.51]

Nitrogen mustard is clinically used for the treatment of lymphomas and some forms of lung cancer. The major indication for mechlorethamine is Hodgkin s disease as a part of the MOPP regimen (mechlorethamine + vincristine (oncovin) + procarbazine + prednisone). The usual dose consists of 6 mg/m2 on days 1 and 8. This drug has pronounced hematological toxicity (myelo-suppression). [Pg.54]

Clinical trials showed therapeutic efficacy in a broad spectrum of tumors these include SCLC, testicular tumors, sarcomas, breast cancer, renal cell cancer, pancreatic tumors and lymphomas. Ifosfamide is less myelosuppressive than cyclophosphamide but is more toxic to the bladder. Therefore it is recommended that ifosfamide is coadministered with the thiol compound mesna to avoid hemorrhagic cystitis and to reduce the risk of developing bladder cancer. Other side effects include neurotoxicity and myelosuppression. [Pg.55]

Carmustine is a bicyclohexylnitrosourea (BCNU, Fig. 3) with broad spectrum of antineoplastic activity (e.g., lymphomas, multiple myeloma, sarcomas, brain tumors, gastrointestinal tumors, melanomas). At doses of 80-200 mg/m2 it is given i.v. at 6 week s intervals. [Pg.56]

Lomustine (2-chlorethyl-3 cyclohexyl-1 -nutrosourea, CCNU, Fig 3) is a nitrosourea for oral application. It is used for the treatment of Hodgkin s lymphomas, brain tumors and bronchial carcinomas at a dose of 3.5 mg/kg (130 mg/m2) repeated in 6-8 weeks intervals. [Pg.56]

Thiotepa is chemically less reactive than the nitrogen mustards. It has antineoplastic activity against ovarian and breast cancers as well as lymphomas. However, it has been largely supplanted by cyclophosphamide and other nitrogen mustards. [Pg.56]

Bendamustine is a useful antineoplastic drug for the treatment of non-Hodgkin s lymphomas, multiple myeloma and as a partner drug in the combination therapy of some solid tumors. The cross-resistance with other alkylating drugs is not complete. Myelosuppression and lymphocytopenia is its main dose-limiting toxicity. [Pg.57]

Liposomal encapsulation of DOX or DNR Preferred anthracycline delivery to the tumor Breast cancer, ovarian cancer, AIDS-related Kaposi s sarcoma, multiple myeloma (pegylated liposomal DOX). Breast cancer (uncoated liposomal DOX). AIDS-related Kaposi s sarcoma, acute mye-loblastic leukemia, multiple myeloma, non-Hodgkin s lymphomas (uncoated liposomal DNR)... [Pg.95]

MTX is part of curative therapeutic schedules for acute lymphoblastic leukemias (ALL), Burkitt s lymphoma, and choriocarcinoma. It was also used in adjuvant therapy of breast cancer. High dose MTX with leucovorin rescue can induce about 30% remissions in patients with metastatic osteogenic sarcoma. MTX is one of the few antineoplastic drugs that can be safely administered intrathecally for the treatment of meningeal metastases and leukemic infiltrations (routine prophylaxis in ALL). In addition, MTX can be used as an immunosuppressive agent for the treatment of severe rheumatoid arthritis and psoriasis. [Pg.148]

Cytarabine is used in the chemotherapy of acute myelogenous leukemia, usually in combination with anthracyclines, thioguanine, or both. It is less useful in acute lymphoblastic leukemia and lymphomas and has marginal activity against other tumors. Myelosuppres-sion is a major toxicity, as is severe bone marrow hypoplasia nausea and mucositis may also occur. [Pg.151]


See other pages where Lymphoma lymphoma is mentioned: [Pg.2441]    [Pg.2441]    [Pg.144]    [Pg.2441]    [Pg.2441]    [Pg.144]    [Pg.165]    [Pg.42]    [Pg.132]    [Pg.119]    [Pg.489]    [Pg.491]    [Pg.158]    [Pg.37]    [Pg.437]    [Pg.438]    [Pg.445]    [Pg.308]    [Pg.284]    [Pg.319]    [Pg.343]    [Pg.60]    [Pg.8]    [Pg.190]    [Pg.54]    [Pg.55]    [Pg.56]    [Pg.93]    [Pg.93]    [Pg.138]    [Pg.150]   
See also in sourсe #XX -- [ Pg.324 ]




SEARCH



ABVD regimen, lymphomas

AIDS-associated lymphoma

AIDS-related lymphoma

Adult T-cell leukaemia/lymphoma

Adult T-cell lymphoma

Advanced metastatic lymphoma

Against P-388 (mouse lymphoma

Alkylating agents lymphomas

Anaplastic large-cell lymphoma

Anaplastic lymphoma

Anaplastic lymphoma kinase

Anti-B-cell lymphoma

Association with malignant lymphoma

B cell lymphoma protein

B cell lymphoma-2 (Bcl

B lymphoma

B-cell lymphomas

Bleomycin lymphomas

Brain lymphoma

Burkitf s lymphoma

Burkitt lymphoma

Burkitt’s lymphoma

Burkitt’s lymphoma cell lines

CHOP regimen, lymphomas

Cancer Lymphomas Malignancies Prostate

Cancer cell lines mouse lymphoma

Cancer lymphoma

Cancer non-Hodgkin’s lymphoma

Carbamazepine lymphoma

Carcinoma lymphomas

Centrocytic lymphoma

Chemotherapy in non-Hodgkin’s lymphoma

Childhood lymphomas/leukemias

Chromosomal translocations lymphoma-specific

Classical Hodgkin lymphoma

Cutaneous T-cell lymphoma

Cutaneous T-cell lymphomas. See

Cutaneous anaplastic large-cell lymphoma

Cyclophosphamide lymphomas

Cytotoxic antibiotics lymphomas

Dalton lymphoma cells

Dalton s lymphoma ascites

Detection of Anaplastic Large Cell Lymphoma

Detection of Follicular Lymphoma

Detection of Mantle Cell Lymphoma

Diffuse large B-cell lymphoma

Diffuse large-cell lymphoma

Doxorubicin lymphomas

Duodenum lymphoma

Effusion lymphoma

Enteropathy-type T-cell lymphoma

Epstein-Barr virus Hodgkin lymphoma

Extranodal NK/T-cell lymphoma, nasal

Extranodal marginal zone B-cell lymphoma

Extranodal marginal zone lymphoma

Extranodal marginal zone lymphoma mucosa-associated lymphoid tissue

Follicular Lymphoma

Follicular large cell lymphoma

Follicular small cleaved cell lymphoma

Gastric B-cell lymphoma

Gastric lymphoma

Glycolipid lymphoma cell

Hepatosplenic T-cell lymphoma

Hodgkin lymphoma antibodies

Hodgkin lymphoma cytokines

Hodgkin lymphoma differential diagnosis

Hodgkin lymphoma mixed-cellularity

Hodgkin lymphoma types

Hodgkin’s lymphoma

Hodgkin’s lymphoma B-cells

Immunoblastic lymphoma

In non-Hodgkin’s lymphoma

Infiltrative lymphomas

Intravascular lymphoma

L5178Y mouse lymphoma assay

Large cell lymphoma

Lennert lymphoma

Leukemia and Lymphoma Society

Leukemia and lymphoma

Leukemia/lymphoma

Lungs MALT-type lymphomas

Lymphohematopoietic study of workers exposed to benzene including multiple myeloma, lymphoma and chronic lymphatic leukemia

Lymphoma

Lymphoma

Lymphoma 932 INDEX

Lymphoma Hodgkin

Lymphoma Subject

Lymphoma advanced follicular

Lymphoma aggressive

Lymphoma azathioprine

Lymphoma benzene-induced

Lymphoma case study

Lymphoma cells

Lymphoma chemotherapy

Lymphoma chronic lymphocytic

Lymphoma clinical features

Lymphoma clinical trials

Lymphoma definition

Lymphoma differential diagnosis

Lymphoma drugs that cause

Lymphoma gastrointestinal

Lymphoma genetic factors

Lymphoma hepatosplenic

Lymphoma immunological

Lymphoma indolent

Lymphoma intestinal

Lymphoma lines

Lymphoma localized follicular

Lymphoma lymphocytic

Lymphoma lymphoplasmacytic

Lymphoma mediastinal

Lymphoma nervous system

Lymphoma non-Hodgkin

Lymphoma pleural

Lymphoma primary cutaneous anaplastic

Lymphoma primary effusion

Lymphoma pyothorax-associated

Lymphoma radiolabeling

Lymphoma salvage therapy

Lymphoma small-cell lymphocytic

Lymphoma staging

Lymphoma subcutaneous

Lymphoma, gene therapy trials

Lymphoma, paraproteins

Lymphoma, proteomics

Lymphoma-binding peptide

Lymphoma/leukemia, lymphoblastic

Lymphomas Hodgkin lymphoma

Lymphomas anaplastic large-cell lymphoma

Lymphomas chronic lymphocytic leukemia/small

Lymphomas classical Hodgkin lymphoma

Lymphomas cutaneous anaplastic large-cell lymphoma

Lymphomas diffuse large-cell lymphoma

Lymphomas expression profiling

Lymphomas extranodal marginal zone lymphoma

Lymphomas follicular lymphoma

Lymphomas leukemia/lymphoma

Lymphomas lymphocytic lymphoma

Lymphomas mantle cell lymphoma

Lymphomas marginal zone lymphoma

Lymphomas mortality rate

Lymphomas mucosa-associated lymphoid tissue

Lymphomas nodal marginal zone lymphoma

Lymphomas nodular lymphocyte predominant Hodgkin

Lymphomas nuclear factor

Lymphomas splenic marginal zone lymphoma

Lymphomas squamous cell, treatment

Lymphomas treatment

Lymphomas, malignant

MALT lymphoma

MALT lymphoma lymphoid tissue

MOPP regimen, lymphomas

Malformation lymphoma

Malignancies, hematologic Cancer Leukemia Lymphomas

Malignancy/cancer leukemia/lymphomas

Malignant disease lymphomas

Malignant lymphoma and phenoxy herbicides

Malignant lymphoma, risk from exposure

Mammalian Lymphoma Test

Mantle cell lymphoma

Marginal zone B-cell lymphoma

Marginal zone B-cell lymphoma of MALT

Marginal zone lymphoma

Marine lymphoma

Marine lymphoma cytotoxicity against

Mitoxantrone in non-Hodgkin’s lymphoma

Mouse Lymphoma Test

Mouse lymphoma

Mouse lymphoma assay

Mouse lymphoma mutagenesis

Mouse lymphoma tk test

Mouse lymphoma tk+/- assay

Murine lymphomas

NK/T cell lymphoma

NLPHL Hodgkin lymphoma

Nervous system tumors lymphoma

Nodal marginal zone B-cell lymphoma

Nodal marginal zone lymphoma

Nodular lymphocyte predominance Hodgkin lymphoma

Non-Hodgkin’s lymphoma

Non-Hodgkin’s lymphoma B-cell

Non-Hodgkin’s lymphoma classification

Non-Hodgkin’s lymphoma rituximab

Non-Hodkin’s lymphoma

NonHodgkin s lymphoma

Noncleaved cell lymphoma

Ovarian lymphoma

Pediatric lymphomas/leukemias

Peripheral T-cell lymphoma

Plant alkaloids lymphomas

Precursor B lymphoblastic leukemia/lymphoma

Prednisone lymphomas

Primary mediastinal large B-cell lymphoma

Primary thyroid lymphoma

Raji lymphoma cells

Revised European American Lymphoma

Revised European American Lymphoma REAL) classification

Sarcomas lymphoma

Skin lymphoma

Small B-cell lymphoma

Small lymphocytic lymphoma

Small-cell malignant lymphomas

Splenic marginal zone lymphoma

Stomach Lymphoma

Susceptible Burkitts lymphoma

T-cell leukemia-lymphoma

T-cell lymphoma

Thymic lymphoma

Vinblastine lymphomas

Vincristine lymphomas

© 2024 chempedia.info